Opinion|Videos|March 21, 2024
Resources for Educating Patients with Myeloma
Focusing on patient education, the panel outlines resources available to help patients with multiple myeloma navigate their treatment journey.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutant HR+/HER2– Breast Cancer
5